Clinical Trial Update: B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating B-Lymphocyte Stimulator (BLyS) for selective IgA deficiency has completed. The study was sponsored by the National Cancer Inst…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Deficiency

Drugs mentioned

• B-Lymphocyte Stimulator (BLyS) (BAFF)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: IgA Deficiency | Phase 1 | Status: COMPLETED